Phytochemicals on "Metabolic Aging" in Older Overweight Adults
NCT ID: NCT04919876
Last Updated: 2021-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2016-11-01
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of a Longevity Supplement on Aging and Photoaging
NCT05262036
Can Fish Oil and Phytochemical Supplements Mimic Anti-Aging Effects of Calorie Restriction?
NCT01752868
A Dietary Supplement Examined for Anti-ageing Effects
NCT06714162
Fisetin Supplementation for Healthy Aging
NCT07195318
The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.
NCT06907329
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Specific Aim 1: To determine the extent to which supplemental fruit and vegetable concentrates will shift the mitochondrial capacity of peripheral blood mononuclear cells in older, overweight older adults toward that of young, lean adults.
Specific Aim 2: To determine the extent to which supplemental fruit and vegetable concentrates will shift the plasma metabolomic signature of older, overweight adults toward that of young, lean adults.
The experimental design is a randomized, double-blind, placebo-controlled, parallel design, controlled feeding trial. This trial will enroll 40 older adults, as well as 20 younger adults to serve as a reference, to complete the study. They will be generally healthy. The older adults will be ≥55 y and have BMI \>27.0 and \<35 kg/m2, and the younger adults will be 18-30 y and have BMI \>18.5 and \<27 kg/m2. The older subjects will be randomized to receive either placebo (PLA) or fruit/vegetable supplement (FVS) for 6 weeks after a 2-wk run-in period. The younger adults serving as the reference group for the older subjects will only participate in the run-in period and will not receive any dietary supplements. During the whole study, including the run-in period, all subjects will consume provided meals. The total duration of the trial will be \~10 weeks for the older subjects, including screening, 2-wk run-in, and 6 wk of intervention, as well as \~4 weeks for the younger subjects including screening and 2-wk run-in. In addition to consuming the provided meals for 6 weeks, the older volunteers will take an assigned supplement daily. Blood samples of the older volunteers will be collected at the end of the run-in and the end of the 6-wk intervention. These same samples will only be collected from the younger volunteers at the end of the run-in period.
Older subjects will be randomly assigned to receive one of the supplements (PLA vs. FVS) after their eligibility is confirmed. A randomization scheme will be prepared by a biostatistician using a standardized computer program for two treatment groups using a parallel design.
The study supplements will be generously provided by Juice PLUS (Collierville, TN). A matching placebo product will be manufactured by the Juice PLUS under the FDA GMP guidelines. The main ingredient of the placebo will be microcrystalline cellulose-containing 0.5% magnesium stearate. The Juice PLUS products that will be used in this intervention have been marketed in the US. Microcrystalline cellulose and magnesium stearate have a GRAS status under FDA Code of Federal Regulations (CFR) title 21. FVS in a capsule form will be the combination of Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend, and Juice Plus+ Berry Blend. All Juice Plus+ supplements contain a fine, granular powder, mainly from botanical ingredients. This powder is encapsulated in a size 00 gelatin capsule. These three formulas will be blended to produce a uniform brown powder and packaged into study opaque capsules.
Juice Plus+ Garden Blend consists of vegetable juice powder and pulp from carrot, parsley, beet, kale, broccoli, cabbage, spinach, oat, rice, and tomato; gelatin, glucomannan, calcium ascorbate, mixed tocopherols, calcium carbonate, garlic powder, Spirulina Pacifica, natural mixed carotenoids, natural enzyme blend, Lactobacillus acidophilus, folic acid. The powder looks pale green in color and smells like cabbage. Juice Plus+ Orchard Blend consists of fruit juice powder and pulp from apple, orange, pineapple, cranberry, peach, acerola cherry, beet, prune, date, and papaya; gelatin, calcium ascorbate, citrus pectin, citrus bioflavonoids, glucomannan, natural mixed carotenoids, natural enzyme blend, bromelain, papain, mixed tocopherols, Lactobacillus acidophilus, folic acid. The powder looks pink in color and smells like apple/cranberry. Juice Plus+ Berry Blend consists of fruit juice and pulp powder of Concord grape, blueberry, cranberry, blackberry, bilberry, raspberry, black currant, elderberry, cocoa powder, pomegranate powder, green tea, ginger root, grape seed, and artichoke leaf powder, gelatin, mixed tocopherols, calcium ascorbate, natural enzyme blend, silicon dioxide, vegetable-derived magnesium stearate, citrus bioflavonoids from tangerine, folic acid. The powder looks purple in color and smells faintly of berry and cocoa.
During the trial, older subjects will be required to attend 1 screening visit and 3 study visits over 10 weeks, and younger subjects will be required to attend 1 screening visit and 2 study visits over 4 weeks. An initial screening visit (Visit 1) is employed to obtain informed consent and determine each subject's eligibility. A blood sample will be collected only if the subject is fasting \>12 hours. At Visit 2, subjects will begin to consume the provided meals for 2 weeks during the run-in period. At Visit 3, all subjects will be asked to arrive at the study site after fasting for \>12 h, blood will be collected. For younger subjects, the study will complete at end of Visit 3. Older subjects will be randomly assigned to one of 2 supplements, starting on the next day of Visit 3 for 6 weeks. They will be instructed to take 3 capsules each with breakfast and dinner. At Visit 4 (final visit), older subjects will be asked to arrive at the study site after fasting for \>12 h, blood will be collected for analyses.
Younger and older subjects will consume provided meals for 2 and 8 weeks. The study meals will be designed to be comparable to a diet that most average Americans are consuming. Subjects may consume the study meals longer than 2 or 8 weeks because of a visit scheduling conflict or other unexpected events.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
fruit/vegetable supplement (FVS)
The experimental product will be prepared by combing Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend, and Juice Plus+ Berry Blend in an equal proportion.
fruit/vegetable supplement (FVS)
The supplement contains polyphenols, carotenoids, and other phytochemicals present in plant foods.
placebo
The placebo comprises microcrystalline cellulose and 0.5% magnesium stearate.
Placebo
The product does not contain nutrients present in the FVS.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fruit/vegetable supplement (FVS)
The supplement contains polyphenols, carotenoids, and other phytochemicals present in plant foods.
Placebo
The product does not contain nutrients present in the FVS.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age, ≥55 y old
3. BMI, ≥27 and \<35 kg/m2
4. Consume a typical American diet, \<3 servings of combined fruits and vegetables daily
5. Waist:hip ratio \>0.8 for women and \>0.9 for men, and waist:height ratio ≥0.5
6. Willing to consume study meals for 8 wk
7. Do not have allergic reaction to plant foods
8. Willing to take the assigned supplement for 6 wk
Exclusion Criteria
2. Cigarette smoking and/or nicotine replacement use in the last 6 months
3. Intend to be pregnant, pregnancy, and breastfeeding
4. Use of medications known to change lipid metabolism
5. Steroid use, except nasal and non-prescription topical treatments
6. Active treatment for cancer of any type \>1 y, except non-melanoma skin cancer
7. Have an immunodeficiency condition
8. Use of immunosuppressive medications within the last 6 months
9. Weekly alcoholic intake \>14 drinks (168 oz beer, 56 oz wine, 14 oz hard liquor)
10. Drugs known to influence fecal microbiota: Regular use of fiber supplements such as Metamucil, probiotics, prebiotics, laxatives, stool softeners, H2 blockers, proton pump inhibitors (PPI) or antacids.
11. Antibiotic use within 3 months prior to or during study participation
12. Colonoscopy or colonoscopy prep within 3 months prior to or during study
13. Infrequent (\<3/wk) or excessive (\>3/d) number of regular bowel movements
14. History of a bilateral mastectomy with nodal dissection
15. Consume ≥3 servings of fruits and vegetables daily one average
16. Gastrointestinal diseases, conditions, or medications influencing gastrointestinal absorption including active peptic ulcer disease or inflammatory bowel disease which will be found based on the self-report during the screening visit
17. Diabetes and/or use of diabetes medications
18. Unstable thyroid disease or adjustment of thyroid medication in past 6 months
19. Abnormal values of standard blood biochemistries that interfere with study outcomes based on study physician's discretion
20. Infection or immunization within 30 days prior to study admission
21. Use anticoagulants, such as heparin, warfarin (coumadin), or Plavix in past 6 months
22. On or planning to be on a weight loss regimen
23. Gain or loss of ≥5% body weight in the last 6 months
24. Inability to refrain from ASA/NSAID/Tylenol use x 720 prior to study blood draws
25. Regular use of any dietary supplements containing vitamins, minerals, herbal or other plant-based preparations, fish oil supplements (including cod liver oil) prebiotics, probiotics or homeopathic remedies; however, subjects who are willing to refrain from the use of these supplements 30 days prior to enrollment and throughout the entire study may be considered eligible
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biofortis, Merieux NutriSciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Oliver Chen
Director of Nutrition Science and Biostatistics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oliver Chen, PhD
Role: PRINCIPAL_INVESTIGATOR
Tufts University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jean Mayer USDA Human Nutrition Research Center on Aging
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2920
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.